Press releases

16 August 2021 Regulatory

Stayble Therapeutics AB offentliggör kvartalsrapport för Q2 2021

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021...

02 June 2021 Regulatory

(SE) Kommuniké från årsstämma i Stayble Therapeutics den 2 juni 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet....

17 May 2021 Regulatory

Stayble Therapeutics AB offentliggör kvartalsrapport för Q1 2021

Göteborg, 17 maj 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för första kvartalet (januari – mars) 2021...

03 May 2021 Regulatory

Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning 6 i Göteborg. Inregistrering till...

03 May 2021 Regulatory

Stayble publishes the Annual Report for 2020

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*....

28 April 2021

Stayble strengthens its team by recruiting VP CMC and Regulatory Affairs

Stayble Therapeutics announced today that the company is strengthening its team by recruiting Dr. Sara Richardson in the newly created role VP CMC and Regulatory Affairs. Dr. Richardson will primarily...

21 April 2021 Regulatory

Stayble provides update on the ongoing Phase 2b study due to the covid-19 pandemic

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to the covid-19 pandemic and the stric...

10 March 2021

Stayble appoints Professor Hans Jörg Meisel as a member of the scientific advisory board

Stayble Therapeutics today announced that the company’s scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel adds furth...

04 March 2021 Regulatory

Last day of trading in BTA

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8 March 2021 and stop day will be on 10 Marc...

22 February 2021 Regulatory

Stayble Therapeutic’s rights issue oversubscribed

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a total of approximately 268 perc...

03 February 2021 Regulatory

Information about the trading in subscription rights and BTA

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection with the Company's ong...

03 February 2021 Regulatory

The subscription period in Stayble Therapeutics’ rights issue begins today

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for existing shareholders (the “Rig...

27 January 2021 Regulatory

Stayble publishes prospectus in connection with the forthcoming rights issue

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday, ...

21 January 2021

Stayble strengthens its scientific advisory board with US-focused key opinion leaders

Stayble Therapeutics today announced that the company’s continue to strengthen its scientific advisory board with two new members – Dr. Aaron Calodney and Dr. Douglas Beall. Their respective exper...

18 December 2020 Regulatory

Stayble resolves on a rights issue in order to ensure the completion of the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019, has resolved on a new iss...

04 December 2020 Regulatory

Stayble Therapeutics AB announces the outcome of the exercise of warrants of series TO1

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price of SEK 12.30 per share. Throug...

17 November 2020

The Subscription Period for the Warrants of Series TO1 in Stayble Therapeutics AB begins Today October 17, 2020

Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right to subscribe one new share in the Company to an exercise pri...

16 November 2020 Regulatory

The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of units where one unit consisted of one newly issued sha...

07 October 2020

Stayble presents at EUROSPINE Annual Meeting 2020

Stayble Therapeutics today announced that Professor Anders Lehmann, VP Development, will give a talk entitled ”Sclerosation of the intervertebral disc using lactic acid in patients with discogenic c...

06 October 2020

Stayble initiates clinical phase 2b study in Spain

Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363. Patient recruitment will commence immediat...

01 October 2020

Stayble's pre-clinical data and the clinical phase 1b study on STA363 is published in the journal SPINE

A scientific article based on pre-clinical studies and the clinical phase 1b study with STA363 has been published in the highly prestigious scientific journal Spine....

31 July 2020 Regulatory

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain c...

02 July 2020

Stayble’s clinical phase 2b study has now also started in the Netherlands

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is...

16 June 2020 Regulatory

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targe...

08 June 2020 Regulatory

Report from the annual general meeting of Stayble Therapeutics on June 8, 2020

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were passed with the required majority....

20 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previ...

01 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previo...

21 April 2020 Regulatory

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019....

14 April 2020

Stayble has, together with APL, completed manufacturing of the investigational drug for the upcoming clinical phase 2b study.

The Company announces that the investigational drug (two doses of STA363 and placebo) now is manufactured and quality assured by our partner APL....

17 March 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from...

17 March 2020

Stayble has submitted applications to regulatory authorities in Spain for start of the Phase 2b clinical trial.

The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities in Sp...

09 March 2020

Stayble has submitted applications to regulatory authorities in The Netherlands for start of the Phase 2b clinical trial.

The company can announce that an important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities and ethical comm...

09 March 2020

The trade in Stayble’s shares and warrants on Nasdaq First North Growth Markets commences today

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North Growth Market. The share is traded und...

06 March 2020

Stayble appoints Mangold as Liquidity Provider

Stayble Therapeutics AB (”Stayble” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company's share on Nasdaq First North Growth Market with first day of tr...

04 March 2020 Regulatory

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on Nasdaq First North Gro...

21 February 2020

Stayble’s new issue was subscribed to 436%

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

17 February 2020

Tomorrow is the last day of subscription for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

04 February 2020

The subscription period for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market begins today and the Company invites to investment events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

31 January 2020

Stayble Therapeutics AB publishes prospectus relating to the issuance of units in connection with the intended listing on Nasdaq First North Growth Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

30 January 2020

Stayble Therapeutics AB intends to be listed on Nasdaq First North Growth Market and carries out a new issue in connection to the listing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

16 August 2021 Regulatory

Stayble Therapeutics AB offentliggör kvartalsrapport för Q2 2021

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021...

02 June 2021 Regulatory

(SE) Kommuniké från årsstämma i Stayble Therapeutics den 2 juni 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet....

17 May 2021 Regulatory

Stayble Therapeutics AB offentliggör kvartalsrapport för Q1 2021

Göteborg, 17 maj 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för första kvartalet (januari – mars) 2021...

03 May 2021 Regulatory

Kallelse till årsstämma i Stayble Therapeutics AB

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning 6 i Göteborg. Inregistrering till...

03 May 2021 Regulatory

Stayble publishes the Annual Report for 2020

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*....

21 April 2021 Regulatory

Stayble provides update on the ongoing Phase 2b study due to the covid-19 pandemic

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to the covid-19 pandemic and the stric...

04 March 2021 Regulatory

Last day of trading in BTA

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8 March 2021 and stop day will be on 10 Marc...

22 February 2021 Regulatory

Stayble Therapeutic’s rights issue oversubscribed

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a total of approximately 268 perc...

03 February 2021 Regulatory

Information about the trading in subscription rights and BTA

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection with the Company's ong...

03 February 2021 Regulatory

The subscription period in Stayble Therapeutics’ rights issue begins today

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for existing shareholders (the “Rig...

27 January 2021 Regulatory

Stayble publishes prospectus in connection with the forthcoming rights issue

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday, ...

18 December 2020 Regulatory

Stayble resolves on a rights issue in order to ensure the completion of the ongoing phase 2b study

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019, has resolved on a new iss...

04 December 2020 Regulatory

Stayble Therapeutics AB announces the outcome of the exercise of warrants of series TO1

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price of SEK 12.30 per share. Throug...

16 November 2020 Regulatory

The Exercise Price for the Warrants of Series TO1 in Stayble Therapeutics AB has been set to SEK 12,30

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of units where one unit consisted of one newly issued sha...

31 July 2020 Regulatory

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain c...

16 June 2020 Regulatory

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targe...

08 June 2020 Regulatory

Report from the annual general meeting of Stayble Therapeutics on June 8, 2020

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were passed with the required majority....

20 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previ...

01 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previo...

21 April 2020 Regulatory

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019....

17 March 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from...

04 March 2020 Regulatory

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on Nasdaq First North Gro...